Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa

This publication has 9 references indexed in Scilit:

• Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial
  Vaccine, 1990
• Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.
  The Journal of Experimental Medicine, 1990
• Haemophilus influenzae infections and whooping cough
  The Lancet, 1990
• Mutants of Pertussis Toxin Suitable for Vaccine Development
  Science, 1989
• Serospecific protection of mice against intranasal infection with Bordetella pertussis
  Vaccine, 1989
• Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide
  The Journal of Pediatrics, 1988
• Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden
  The Pediatric Infectious Disease Journal, 1988
• The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells
  Journal of Biological Standardization, 1985
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
  Nature, 1970